Although patients with severe immunodeficiency and hematological malignancies has been considered at highest risk for invasive fungal infection, patients with severe pneumonia due to influenza, and severe acute respiratory syndrome coronavirus (SARS-CoV) are also at a higher risk of developing invasive pulmonary aspergillosis (IPA). Recently, reports of IPA have also emerged among SARS-CoV-2 infected patients admitted to intensive care units (ICUs). Here, we report a fatal case of probable IPA in an acute myeloid leukemia patient co-infected with SARS-CoV-2 and complicated by acute respiratory distress syndrome (ARDS). Probable IPA is supported by multiple pulmonary nodules with ground glass opacities which indicate halo sign and positive serum galactomannan results. Screening studies are needed to evaluate the prevalence of IPA in immunocompromised patients infected with SARS-CoV-2. Consequently, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples of COVID-19 patients with timely and targeted antifungal therapy based on early clinical suspicion of IPA are highly recommended.

尽管患有严重免疫缺陷和血液系统恶性肿瘤的患者被认为是侵袭性真菌感染的最高风险，但流感引起的重症肺炎和严重急性呼吸系统综合症冠状病毒（SARS-CoV）患者患侵袭性肺曲霉病的风险也更高。国际音标)。最近，在重症监护病房 (ICU) 收治的 SARS-CoV-2 感染患者中也出现了 IPA 的报道。在这里，我们报告了一起感染 SARS-CoV-2 并并发急性呼吸窘迫综合征 (ARDS) 的急性髓性白血病患者可能发生 IPA 的致命病例。可能的 IPA 由多个肺结节支持，具有磨玻璃影，表明晕征和血清半乳甘露聚糖结果阳性。需要进行筛查研究来评估感染 SARS-CoV-2 的免疫功能低下患者中 IPA 的患病率。因此，测试是否存在强烈建议在早期临床怀疑 IPA 的基础上，对COVID -19 患者的连续血清样本中的下呼吸道分泌物和半乳甘露聚糖进行及时和靶向抗真菌治疗。